Recently, novel BCL-XL proteolysis targeting chimeras (PROTACs) have been developed to degrade BCL-XL in cancer cells but not platelets, as it targets BCL-XL to the VHL E3 ligase for ubiquitination and proteasomal degradation and platelets express very low levels of VHL [61, 62]. Here, BCL2L1 is linked to cancer.